Key Points

• The discovery rule can preserve a Depo-Provera meningioma lawsuit years or decades after the last injection by delaying when the statute of limitations begins to run. 
• The clock typically starts when a woman knew, or reasonably should have known, that her meningioma was linked to Depo-Provera. The FDA’s December 2025 label update is the strongest trigger date for most U.S. plaintiffs. 
• Women who assume their filing deadline has passed often still qualify and should have an attorney evaluate their timeline before ruling themselves out. 

Why It Matters

For thousands of American women, the assumption that “too much time has passed” is the only thing standing between them and a viable Depo-Provera meningioma claim. The discovery rule exists precisely to protect patients in this situation, where a slow-growing tumor and a hidden product risk make it impossible to connect the two until years later. 

The Discovery Rule in Depo-Provera Meningioma Lawsuits

Thousands of women across the United States used Depo-Provera in the 1990s, 2000s, and 2010s and are only now learning that the birth control shot has been linked to meningioma brain tumors. For many of these women, the meningioma diagnosis came years, and sometimes decades, after their last injection. 

The common assumption is that too much time has passed to take legal action. That assumption is often wrong. 

A legal principle called the discovery rule allows women in most states to file a Depo-Provera lawsuit even when their meningioma was diagnosed long after they stopped using the contraceptive. The filing clock does not always start when the shot was given. In many cases, it starts when the woman learned, or reasonably should have learned, that her tumor was connected to Depo-Provera. 

If you or a loved one used the Depo-Provera birth control shot and were later diagnosed with a meningioma, you may still qualify to file a lawsuit and receive compensation.

For more information about how the discovery rule may affect your ability to file a Depo-Provera meningioma lawsuit or to start the process of filing claim today, contact the lawyers at Hissey Mulderig & Friend by calling our office toll-free at 1-866-806-8117, or send us a message using our free Depo-Provera claims submission form on the right side of this page. 

What Is the Discovery Rule?

The discovery rule is a legal doctrine that delays the start of the statute of limitations until the date a person knew, or reasonably should have known, that they suffered an injury and that the injury was caused by the defendant’s product or conduct. 

In a typical personal injury case, the statute of limitations begins on the date the injury occurred. A standard two-year deadline would run out two years after the date of the accident. 

Drug injury cases work differently. With prescription medications, the connection between a drug and a long-term health condition is often impossible to identify at the time the medication was taken.  

A woman who received a Depo-Provera injection in 2008 had no way of knowing then that the shot might cause a brain tumor years later. The science that established the link between Depo-Provera and meningioma was not widely published until 2024. 

The discovery rule protects injured patients who could not reasonably have connected their illness to a defective product until well after the standard filing deadline would have passed. 

Why the Discovery Rule Matters for Depo-Provera Cases

Meningiomas are slow-growing tumors that form on the protective layers surrounding the brain. They can take years or even decades to produce symptoms. A woman exposed to high-dose progestin through repeated Depo-Provera injections in her 20s or 30s may not be diagnosed with a meningioma until her 40s, 50s, or 60s. 

The scientific link between Depo-Provera and meningioma was not broadly recognized in the United States until a landmark study was published in The BMJ in March 2024. That study found that women who used medroxyprogesterone acetate, the active ingredient in Depo-Provera, for more than a year faced a significantly increased risk of intracranial meningioma. The FDA did not formally add meningioma to the Depo-Provera warning label until December 2025. 

For most American women diagnosed with meningioma before 2024, no public information was available connecting their tumor to the birth control shot they had received years earlier. Many learned of the link only when they saw news coverage or attorney advertising, often long after their initial diagnosis. 

The discovery rule is what gives these women a path to file a lawsuit today. 

The Discovery Rule Starts the Clock for Depo-Provera Cases

In a Depo-Provera meningioma case, the statute of limitations under the discovery rule generally begins when a woman knew, or reasonably should have known, three things: 

1. She was diagnosed with a meningioma. 
2. She used Depo-Provera (or its generic equivalent, medroxyprogesterone acetate). 
3. There is a potential causal connection between her Depo-Provera use and her meningioma. 

For most women, the third element is the controlling factor. A woman diagnosed with a meningioma in 2018 may have had no reason to suspect a connection to a birth control shot she received a decade earlier. Under the discovery rule, the clock does not begin running on her right to file until she had a reasonable basis to make that connection. 

The specific standard varies by state. Some states apply a strict “knew or should have known” test. Others use a more patient-friendly standard that requires actual awareness of the link. A handful of states do not apply the discovery rule at all in product liability cases. Several states also impose an outer deadline called a statute of repose, which can shorten the available filing window. 

This is why state-specific analysis matters. Hissey Mulderig & Friend has prepared a complete Depo-Provera lawsuit statute of limitations guide for women evaluating their options state by state. 

Common Scenarios: Women Who May Still Qualify

Many women rule themselves out of a Depo-Provera lawsuit because they assume the filing deadline has already passed. The following scenarios describe women who often still qualify under the discovery rule: 

• A woman who received Depo-Provera injections from 1998 to 2004 and was diagnosed with a parasagittal meningioma in 2022. 
• A woman who used the Depo shot for several years in her late 20s, had a meningioma surgically removed in 2019, and only recently learned the tumor may have been connected to her contraceptive history. 
• A woman who took Depo-Provera throughout the 2000s, was diagnosed with a sphenoid wing meningioma in 2015, and underwent radiation treatment without any provider ever mentioning a drug-related cause. 
• A woman whose mother used Depo-Provera and was diagnosed with a fatal meningioma years later. Wrongful death claims may also be available under the discovery rule for surviving family members. 
• A woman who received a Depo injection five or ten years ago, has experienced ongoing headaches or vision changes, and was diagnosed with a meningioma in the past 12 months. 

In each of these situations, a conventional two- or three-year filing deadline appears to have run out. The discovery rule often resets that clock to the date the connection between Depo-Provera and the tumor first became reasonably knowable. 

Statute of Repose: An Important Caveat

Even where the discovery rule applies, some states impose a statute of repose. A statute of repose sets an outer time limit measured from a specific event, often the date of sale, last use, or first exposure, beyond which no claim can be filed regardless of when the injury was discovered. 

For Depo-Provera claims, repose periods most commonly run from the date of the last injection. These periods generally range from 10 to 15 years in states that have them, although many states do not impose a repose period for pharmaceutical product liability claims at all. 

Because the discovery rule and the statute of repose interact differently in every state, a Depo-Provera attorney should review your specific timeline before you assume you have either qualified or run out of time. 

Options for Women Who Think They May Still Qualify

Even with the protection of the discovery rule, time still matters. The longer a woman waits after recognizing the potential link between her Depo-Provera use and her meningioma, the greater the risk that her filing window will close. 

If you used Depo-Provera and were diagnosed with a meningioma at any point, do not assume you are too late. Take three steps: 

1. Gather what records you can, including pharmacy histories, insurance records, and your meningioma diagnostic imaging. Incomplete records are not a barrier to filing, and an experienced attorney can help recover documentation on your behalf. 
2. Avoid making any sworn or written statements about when you first connected your tumor to your Depo use. 
3. Contact a Depo-Provera meningioma attorney to find out if you qualify to take legal action. 

Contact a Depo-Provera Attorney for a Free Case Evaluation

The discovery rule, statutes of repose, and fraudulent-concealment doctrine all affect whether a Depo-Provera meningioma claim is timely. Because each of these doctrines varies by state and depends on the specific dates of injection, diagnosis, and awareness of the link, the only reliable way to know whether you still qualify is to speak with an attorney. 

Women who used Depo-Provera or an authorized generic and were later diagnosed with a meningioma, regardless of how long ago the injections occurred, may still have legal options worth exploring. 

Our law firm, Hissey Mulderig & Friend, is currently evaluating claims involving women diagnosed with meningioma brain tumors after using the Depo-Provera shot. 

To speak with an attorney about your case, find out whether you qualify to take legal action, or start the process of filing your claim today, contact the lawyers at Hissey Mulderig & Friend by calling our office toll-free at 1-866-806-8117, or send us a message using the free claims submission form at the top of this page. 

Disclaimer: This article is general legal information, not legal advice. The application of the discovery rule, statute of limitations, and statute of repose in a Depo-Provera meningioma case is fact-specific and depends on the date of the woman’s last Depo-Provera injection, the date of meningioma diagnosis, the state where the cause of action arose, and the specific tolling and discovery doctrines in effect in that state. Anyone considering filing a Depo-Provera meningioma claim may wish to consult with an attorney without delay, because many state filing deadlines are short and even a brief delay can permanently foreclose recovery.